SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN)
BTRN 27.73+0.1%Dec 31 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (238)3/31/1999 1:14:00 PM
From: Pseudo Biologist   of 1475
 
I'll let Rick handle the difficult ones -g-

No, BTRN is not involved with CD40L, but its anti-CD2 molecule (developed with MEDI) would target a similar range of autoimmune and/or transplantation-related conditions. So, this may be seen as a competitor (although I do not know if BTRN's molecule itself is expected to have an application in SLE - let's leave *this* difficult question for Rick!)

And by the way, thanks for sharing your table of biotechs with cash, revenues, etc. Very useful.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News